MeSH term
Frequency | Condition_Probility | Animals | 66 | 0.0 |
Blotting, Western | 3 | 0.0 |
Cell Division | 7 | 0.0 |
Cell Line | 17 | 0.0 |
Cell Movement | 2 | 0.0 |
Cell Separation | 3 | 0.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Humans | 119 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Mice | 37 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Rats | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 62 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
Coculture Techniques | 3 | 0.0 |
Female | 54 | 0.0 |
Mice, Inbred C57BL | 12 | 0.0 |
Vero Cells | 2 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
Morphogenesis | 2 | 0.0 |
Mutation | 3 | 0.0 |
Plaque Assay | 2 | 2.0 |
Temperature | 2 | 0.0 |
Buthionine Sulfoximine/pharmacology | 2 | 5.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Male | 52 | 0.0 |
Neoplasm Transplantation | 4 | 0.0 |
Transfection | 2 | 0.0 |
Tumor Cells, Cultured | 16 | 0.0 |
Cells, Cultured | 25 | 0.0 |
Copper/pharmacology | 3 | 5.0 |
DNA Probes | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
*Physical Chromosome Mapping | 2 | 1.0 |
Sperm Count | 3 | 4.0 |
Sperm Motility | 5 | 10.0 |
Spermatozoa/drug effects/*physiology | 2 | 20.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Time Factors | 7 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Cell Division/drug effects | 5 | 0.0 |
Cell Survival/drug effects | 3 | 0.0 |
Child | 4 | 0.0 |
Comparative Study | 29 | 0.0 |
Tumor Cells, Cultured/*drug effects | 2 | 4.0 |
Blotting, Northern | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Gene Library | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Mice, Inbred Strains | 4 | 0.0 |
*Neoplasm Proteins | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Down-Regulation | 3 | 0.0 |
Adolescent | 5 | 0.0 |
Adult | 15 | 0.0 |
English Abstract | 6 | 0.0 |
Fertilization in Vitro | 7 | 5.0 |
Age Factors | 2 | 0.0 |
Middle Aged | 10 | 0.0 |
Oocytes/*cytology | 3 | 27.0 |
In Vitro | 5 | 0.0 |
Neoplasm Metastasis | 3 | 0.0 |
Organ Culture Techniques | 5 | 1.0 |
Base Sequence | 8 | 0.0 |
DNA Primers | 3 | 0.0 |
Phenotype | 4 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Aged | 7 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Melanoma/*metabolism | 2 | 3.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Cattle | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Species Specificity | 3 | 0.0 |
Oxidation-Reduction | 8 | 0.0 |
Probucol/pharmacology | 3 | 37.0 |
Vitamin E/pharmacology | 3 | 9.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Rabbits | 5 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Culture Media | 21 | 3.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Macrophages/*metabolism | 3 | 1.0 |
Cross Reactions | 4 | 0.0 |
Blood Platelets/drug effects/*physiology | 2 | 4.0 |
Cell Membrane/physiology | 2 | 1.0 |
Swine | 2 | 0.0 |
Cryoprotective Agents/*pharmacology | 2 | 50.0 |
Microscopy, Electron | 5 | 0.0 |
Viral Envelope Proteins/*immunology | 2 | 5.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Pregnancy | 8 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Drug Resistance | 3 | 0.0 |
Organoplatinum Compounds/*pharmacology | 2 | 12.0 |
Fertilization in Vitro/*drug effects | 2 | 28.0 |
Sperm Motility/*drug effects | 2 | 11.0 |
Autoantigens/*immunology | 2 | 1.0 |
Clone Cells | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 15 | 0.0 |
Culture Media/*chemistry | 3 | 37.0 |
Embryonic and Fetal Development/*physiology | 2 | 4.0 |
*Fertilization in Vitro | 5 | 4.0 |
Cysteine/pharmacology | 2 | 16.0 |
Cystine/pharmacology | 2 | 100.0 |
Glutathione/*physiology | 2 | 22.0 |
Kinetics | 8 | 0.0 |
Lipoproteins, LDL/*metabolism | 5 | 2.0 |
Cattle/*genetics | 2 | 1.0 |
*Chromosome Mapping | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Epithelial Cells | 3 | 0.0 |
Evaluation Studies | 7 | 1.0 |
Cats | 2 | 0.0 |
Glycosylation | 2 | 0.0 |
Oxidative Stress | 2 | 0.0 |
Umbilical Veins | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Melanoma, Experimental/*immunology | 2 | 28.0 |
*Paternity | 2 | 2.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 4 | 0.0 |
Binding Sites | 2 | 0.0 |
Spermatozoa/*metabolism | 2 | 3.0 |
Sperm Capacitation | 3 | 23.0 |
Sperm Motility/*physiology | 3 | 42.0 |
Cell Survival | 3 | 0.0 |
*Culture Media | 6 | 37.0 |
*Sperm Motility | 6 | 24.0 |
Sperm-Ovum Interactions | 3 | 11.0 |
Lymphocyte Activation | 3 | 0.0 |
T-Lymphocytes/immunology | 3 | 0.0 |
Ploidies | 2 | 0.0 |
Buffers | 2 | 1.0 |
Solutions | 4 | 2.0 |
Cell Survival/physiology | 3 | 1.0 |
Culture Techniques | 3 | 0.0 |
Progesterone/*secretion | 2 | 22.0 |
DNA | 3 | 0.0 |
Pedigree | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Hela Cells | 2 | 0.0 |
Phosphorylation | 3 | 0.0 |
*Virus Assembly | 2 | 8.0 |
Methods | 2 | 0.0 |
Biological Assay | 2 | 0.0 |
Progesterone/*metabolism | 2 | 5.0 |
Serum Albumin/pharmacology | 2 | 5.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
*Neoplasm Metastasis | 3 | 3.0 |
Blastocyst/*cytology | 2 | 50.0 |
Blood | 2 | 1.0 |
Autoantibodies/*analysis | 2 | 0.0 |
Immunoglobulin A/analysis | 2 | 1.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
Immunoglobulin M/analysis | 2 | 0.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Embryo Transfer | 3 | 4.0 |
Fertilization in Vitro/*methods | 3 | 11.0 |
Factor X/*genetics | 2 | 40.0 |
Centrifugation | 2 | 2.0 |
Interferon Type I/*therapeutic use | 2 | 15.0 |
Oocytes/physiology | 2 | 1.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Trypsin/pharmacology | 2 | 1.0 |
Tyrosine/*metabolism | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
